$60.92
2.64% yesterday
Nasdaq, Oct 28, 09:01 pm CET
ISIN
US6402681083
Symbol
NKTR

Nektar Therapeutics Stock price

$60.92
+2.00 3.39% 1M
+49.58 437.36% 6M
+46.97 336.70% YTD
+40.52 198.63% 1Y
+4.52 8.01% 3Y
-177.73 74.47% 5Y
-123.43 66.95% 10Y
-158.98 72.30% 20Y
Nasdaq, Closing price Tue, Oct 28 2025
-1.65 2.64%
ISIN
US6402681083
Symbol
NKTR
Industry

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$1.0b
Net debt
positive
Cash
$175.9m
Shares outstanding
12.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
15.9 | 27.4
EV/Sales
13.5 | 23.4
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
20.0%
Return on Equity
-195.9%
ROCE
-102.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$74.9m | $43.4m
EBITDA
$-137.2m | $-143.8m
EBIT
$-139.1m | $-164.2m
Net Income
$-122.3m | $-151.2m
Free Cash Flow
$-186.1m
Growth (TTM | estimate)
Revenue
-19.5% | -55.9%
EBITDA
-6.6% | -14.6%
EBIT
-3.0% | -26.4%
Net Income
30.9% | -27.1%
Free Cash Flow
-6.1%
Margin (TTM | estimate)
Gross
83.4%
EBITDA
-183.1% | -331.3%
EBIT
-185.7%
Net
-163.2% | -348.4%
Free Cash Flow
-248.3%
More
EPS
$-8.7
FCF per Share
$-14.9
Short interest
9.3%
Employees
61
Rev per Employee
$1.6m
Show more

Is Nektar Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,039 stocks worldwide.

Nektar Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Nektar Therapeutics forecast:

11x Buy
79%
2x Hold
14%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a Nektar Therapeutics forecast:

Buy
79%
Hold
14%
Sell
7%

Financial data from Nektar Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
75 75
20% 20%
100%
- Direct Costs 12 12
67% 67%
17%
63 63
13% 13%
83%
- Selling and Administrative Expenses 78 78
2% 2%
103%
- Research and Development Expense 124 124
12% 12%
166%
-137 -137
7% 7%
-183%
- Depreciation and Amortization 1.97 1.97
69% 69%
3%
EBIT (Operating Income) EBIT -139 -139
3% 3%
-186%
Net Profit -122 -122
31% 31%
-163%

In millions USD.

Don't miss a Thing! We will send you all news about Nektar Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nektar Therapeutics Stock News

Neutral
PRNewsWire
about 2 hours ago
SAN FRANCISCO , Oct. 28, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Thursday, November 6, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m.
Positive
CNBC
about 7 hours ago
CNBC's Brian Sullivan sought to find the companies based in the city that were making investors the most money this year.
Neutral
PRNewsWire
7 days ago
SAN FRANCISCO , Oct. 22, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, in atopic dermatitis has been accepted for a late-breaking oral abstract presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025...
More Nektar Therapeutics News

Company Profile

Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The firm focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.

Head office United States
CEO Howard Robin
Employees 61
Founded 1990
Website www.nektar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today